ABSTRACT: Early exposure to glucocorticoids (GC) has been proposed to disturb hepatic and cardiac function in later life. In the present study, we evaluated early metabolic alterations upon GC treatment that may predispose to long-term abnormalities. Rats were injected with dexamethasone (DEX) at d 1, 2, and 3 after birth and controls received saline (SAL). Rats were killed at 2, 7, and 14 d of age. Compared with SAL, DEX induced lower plasma insulin levels, hyperglycemia, hyperketonemia, and dyslipidemia at 2 d. At the same time, DEX treatment significantly increased expression of gluconeogenic and fatty acid oxidation genes in liver and expression of genes involved fatty acid utilization in heart. At 7 d, DEX-treated rats showed insulin resistance with hyperlipidemia, whereas hepatic and cardiac gene expression patterns were largely normalized. Hyperlipidemia and a significantly increased hepatic triglyceride content in DEX-treated rats were prominent at 14 d without large differences in hepatic and cardiac gene expression patterns. Thus, neonatal DEX administration transiently affects cardiac and hepatic gene expression patterns in suckling rats associated with sustained effects on plasma glucose and lipid concentrations. Whether these early effects of DEX contribute to hepatic and cardiac abnormalities at adult age needs further evaluation. (Pediatr Res 61: [165][166][167][168][169][170] 2007) G C are used to prevent chronic lung disease in immature newborns because of their anti-inflammatory action. However, despite the evident short-term benefit, concern has emerged about potential long-term negative consequences (1,2). Cardiovascular disease is one of the negative consequences proposed to occur after neonatal DEX administration in preterm human newborns, including transient cardiac hypertrophy (3) and hypertension (4). Recent studies conducted in rats have revealed that neonatal DEX administration leads to cardiac dilatation and reduced systolic function at 4 wk (5) and to cardiac hypertrophy at 45 wk of age (6). So far, the molecular mechanism by which postnatal administration of GC induces cardiac dysfunction later in life has remained unknown.
G
C are used to prevent chronic lung disease in immature newborns because of their anti-inflammatory action. However, despite the evident short-term benefit, concern has emerged about potential long-term negative consequences (1, 2) . Cardiovascular disease is one of the negative consequences proposed to occur after neonatal DEX administration in preterm human newborns, including transient cardiac hypertrophy (3) and hypertension (4) . Recent studies conducted in rats have revealed that neonatal DEX administration leads to cardiac dilatation and reduced systolic function at 4 wk (5) and to cardiac hypertrophy at 45 wk of age (6) . So far, the molecular mechanism by which postnatal administration of GC induces cardiac dysfunction later in life has remained unknown.
Epidemiologic studies have raised the "fetal origins of adult disease" hypothesis, stating that early lifestyle factors, imposed by intrauterine or neonatal environment, increase the risk of developing cardiovascular disease and hypertension in later life (7) . In particular, exposure to excess GC during critical early life stages has been implicated as a factor that may program long-term changes in cardiac function, predisposing to adult disease (8) .
The heart requires a continuous energy supply to maintain its contractile function, while its capacity to store energy-rich substrates is limited. Under resting conditions, the adult heart derives about 70% of its energy from lipid oxidation and the remainder from glucose (9) . Several recent studies have demonstrated that altered cardiac energy utilization might be a cause for cardiomyopathy (10, 11) . However, whether cardiac genes involved in energy metabolism are persistently affected during that process has not been reported.
GC administration leads to insulin resistance, hyperglycemia, and dyslipidemia in preterm babies (12) and in experimental animals (13) . The liver performs a crucial role in maintaining lipid and glucose homeostasis. GC administration may lead to hepatic insulin resistance, contributing to hyperglycemia as well as dyslipidemia in rats (14) . Data accumulated in recent years have indicated that GC exposure during early life may cause liver dysfunction in later life, contributing to metabolic derangements (8, 15) and increased risk for cardiovascular disease. Therefore, neonatal GC administration may disturb hepatic energy metabolism with a consequently unbalanced cardiac energy supply. However, available data on hepatic energy metabolism, especially gene expression at neonatal stage, are still quite limited.
In the present study, we investigated the short-term effect of GC, particularly of DEX, on hepatic and cardiac expression of genes involved in energy metabolism in relation to plasma concentrations of metabolic substrates in suckling rats, trying
RESULTS
Neonatal DEX treatment leads to growth retardation in suckling rats. Compared with SAL-treatment, neonatal DEX administration led to a significantly reduced body weight gain, which was manifest already at 24 h after initiation of DEX treatment. A significantly lower body weight was found during the entire experimental period (2-14 d of age) (Fig. 1) . A significantly lower heart weight was noted following DEX administration at all ages (Table 2) . A significantly higher heart weight/body weight ratio was, however, found only at 7 d old rats upon DEX treatment, suggesting transient cardiac hypertrophy at that age. Neonatal DEX treatment led to a significantly higher liver weight/body weight ratio at 2 d of age.
Acute and chronic effects of neonatal DEX treatment on plasma insulin and glucose levels. Hyperglycemia was found at d 2 in rats treated with DEX, however, blood glucose levels decreased to the control level at 7 d and a significantly lower blood glucose level was found at 14 d of age (Table 3) . Compared with the SAL-treated rats, DEX-treated rats showed significantly decreased plasma insulin levels at 2 d of age. Elevated plasma insulin was found at 7-d-old rat pups after DEX treatment, which, combined with normal blood glucose level, indicates an insulin resistant state. No differences in plasma insulin levels were found between SAL-and DEX-treated groups at 14 d of age.
Acute and chronic effects of neonatal DEX treatment on blood lipid profile and ketone bodies concentrations. DEX treatment led to a sustained increase in total plasma cholesterol concentrations (Table 3) . Separation of plasma lipoproteins by FPLC revealed that increased cholesterol at 2 d of age was mainly confined to LDL-and HDL-sized fractions ( Fig. 2A) . In contrast, at 7 and 14 d, cholesterol was more abundantly present in VLDL and LDL-sized fractions (Fig. 2, C and E) . Plasma triglyceride concentrations were low in 2-d-old DEXtreated rats (Table 2) , mainly due to reduction in VLDL-sized fractions (Fig. 2B) . Significantly elevated plasma triglyceride concentrations were observed at 7 d after DEX treatment, with particularly increased amounts of triglycerides in VLDL-sized fractions (Fig. 2D) . No difference was found in plasma triglyceride concentration at 14 d between SAL-and DEXtreated groups (Table 2) . At this point, plasma triglycerides were still predominantly associated with VLDL and less with LDL-and HDL-sized fractions in DEX-treated rats compared with controls (Fig. 2F ). Plasma concentrations of nonesterified fatty acid (NEFA) and ketone bodies were increased in DEXtreated group at 2 d of age, yet, no significant differences existed at 7 and 14 d between both groups. 
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Effects of DEX treatment on hepatic fatty acid and glucose metabolism. Hepatic triglyceride content was significantly decreased at 2-and 7-d-old DEX-treated animals, whereas triglyceride accumulation (steatosis) was clearly present at 14 d (Fig. 3) . ORO staining revealed uniformly distributed fat droplets in liver of DEX-treated rats (Fig. 4, A and B) . PAS staining revealed that DEX treatment led to hepatic glycogen accumulation at d 2 (not shown) and reduced amounts at 14 d of age (Fig. 4, C and D) .
DEX led to increased hepatic mRNA levels of genes involved in fatty acid uptake and control of fatty acid oxidation such as PPAR␣ and carnitine palmitoyltransferase 1A (CPT1A) at 2 d of age, suggesting enhanced hepatic fatty acid oxidation (Fig. 5 ). In contrast, at 7 d, some of these genes were down-regulated, which may be due to a suppressive effect of elevated plasma insulin at that age. Decreased expression of lipogenic genes such as fatty acid synthase (FAS) was noted at 2 d, and sterol regulatory element binding protein 1c (SREBP1c) at 2 and 7 d with DEX treatment. All these alterations were transient and normalized at 14 d of age.
Compared with SAL, DEX increased expression of hepatic gluconeogenic genes at 2 d of age, as characterized by upregulation of PEPCK and G6PHT expression. Increased expression of some other important genes such as glycogen synthase (GS), glucokinase (GK), and glycogen phosphorylase (GP), together with up-regulated G6PHT, at the mRNA level suggests increased rates of hepatic glucose and glycogen cycling at that age. However, although hepatic PEPCK mRNA continued to be higher in 7-d-old DEX-treated rats, decreased 
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G6PHT and glycogen phosphorylase (GP) suggest the decease in glycogen degradation. None of these genes was found to be differently expressed in the liver of 14-d-old rats of both groups (Fig. 5) .
Effects of neonatal DEX treatment on expression of cardiac genes involved in energy metabolism. Confirming a previous study (21) , H&E staining indicated the presence of enlarged cardiomyocyte in 7-d-old rat pups treated with DEX compared with controls (Fig. 6, A and B) , without differences in PAS (Fig. 6, C and D) or ORO staining (data not shown).
Cardiac expression of genes involved in control of fatty acid and lipoprotein uptake and metabolism such as PPAR␣, PPAR[gerds], lipoprotein lipase (LPL), CD36, CPT1A, CPT1B, very LDL receptor (VLDLR), LDL receptor (LDLR), long-chain acyl-CoA dehydrogenase (LCAD), medium chain acyl-CoA dehydrogenase (MCAD), uncoupling protein (UCP) 2 and 3 was found to be significantly increased in hearts of 2-d-old DEX-treated rats, which indicates acute stimulatory effects of DEX on cardiac fatty acid utilization (Fig. 7) . Expression of most of these genes, however, was reduced to control levels at d 7. DEX enhanced cardiac expression of genes involved in glucose transport and glycolysis such as glucose transporter 1 and 4 (GLUT1 and 4), and hexokinase 2 (HK2) at 2 d of age. Particularly cardiac pyruvate dehydrogenase kinase isoenzyme 4 (PDK4) mRNA was increased by DEX. These effects were transient and no significant differences between the groups were seen at 14 d. Increased cardiac gene expression of insulin receptor (IR) at mRNA level was only observed in 2-d-old rats upon DEX treatment.
Postnatal DEX treatment led to an increase in cardiac atrial natriuretic peptide (ANF), desmin, and troponin T (TnnT2) mRNA content at 2 d of age. Thereafter, cardiac ANF and TnnT2 mRNA levels returned to control level at 14 d of age, whereas desmin mRNA content was slightly decreased in DEX-treated rats at that time point. 
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DISCUSSION
Treatment of rat pups postnatally with DEX resulted in acute changes in energy metabolism, both with respect to substrate availability and hepatic and cardiac gene expression profiles. In a substantial number of cases, these changes were transient, i.e. no differences were observed between DEX-and SAL-treated groups at the age of 14 d. On the other hand, there were effects of early overexposure to DEX that persisted until 14 d of age, particularly at the level of plasma and hepatic metabolite concentrations. As a consequence, early exposure to DEX resulted in marked alterations in plasma lipoprotein composition at 14 d of age and a clear hepatic steatosis.
As reported previously (22) , early exposure to DEX resulted in impaired growth: no catch-up growth occurred during the initial 14 d of life. In fact, it has been reported that neonatal exposure to DEX leads to sustained reduction in body weight gain which might be due to suppression of growth hormones and the IGF axis (23, 24) . In the present study, both liver and heart weight were reduced in DEX-treated animals, however, upon normalization to body weight, no differences between DEX-and SAL-treated rats were observed except an increased heart/body weight ratio at 7 d of age. Microscopic examination indicated the presence of cardiac hypertrophy at this time point. There were no apparent signs of cardiac glycogen or fat accumulation observed upon PAS or ORO staining at any age between SAL-and DEX-treated animals.
DEX treatment acutely led to an increase in plasma nonesterified fatty acid concentrations that might be attributable to enhanced lipolysis caused by lower plasma insulin levels. The latter may be a consequence of acute inhibitory effects of DEX on insulin secretion (25) . Lower plasma insulin levels, in turn, might reduce glucose uptake by peripheral tissue. Yet, consistent with previous studies (26) , DEX administration induced hepatic gluconeogenesis by up-regulating PEPCK and G6PHT gene expression at 2 d of age. Reduced glucose uptake by peripheral tissue and increased hepatic gluconeogenesis likely contribute to hyperglycemia at this time point. Interestingly, the cycling between glucose and glucose-6-phosphate, glucose-1-phosphate, and glycogen appeared to be increased as deduced from gene expression profiles, confirming a study conducted by Wajngot et al. (27) in healthy human subjects treated with DEX. This might reflect a regulatory mechanism to limit net hepatic glucose production. In addition, decreased fatty acid synthesis and increased fatty acid oxidation induced by DEX treatment, suggested by the expression level of responsible genes, might contribute to lower hepatic triglyceride content at this age. As reported previously (13) , DEX led to an insulin resistant state at 7 d of age, as characterized by increased plasma insulin concentration and sustained increased hepatic gene expression of PEPCK, although blood glucose level was still kept at normal levels. Hyperinsulinemia might be caused by increased insulin secretion, which has also been found by Nicod et al. (28) in human studies. The molecular mechanism behind these observations is still unclear. Hypertriglyceridemia is frequently encountered in patients with insulin resistance. Data suggest that it is due to an inability of insulin to suppress hepatic VLDL secretion (29) . There were no differences in hepatic "lipid" gene expression between SAL-and DEX-treated animals at 14 d old, indicating no persistent alteration in hepatic gene expression to occur in this experimental setting. However, increased VLDLassociated cholesterol and triglycerides, i.e. an atherogenic lipid profile (30) , persistent until this age. Significantly reduced blood glucose concentration in DEX-treated animals at this age might be due to increased peripheral glucose uptake, yet, this remains to be established experimentally. Consistent with a previous study (31) , hepatic steatosis was observed in 14-d-old animals upon DEX treatment. Whether this condition will persist until adult life and contributes to impaired hepatic insulin sensitivity remains to be determined.
The heart is a preferentially fatty acid-utilizing organ. An impressive amount of data suggest that inappropriately increased fatty acid utilization might be critical for cardiomyopathy in diabetes due to increased oxidative stress and accumulation of toxic fatty acid metabolites (11) . We found that DEX administration led to increased cardiac fatty acid utilization at 2 d of age, as deduced from the elevated expression of genes involved in cardiac fatty acid uptake, transport, and oxidation. Elevated plasma fatty acid and triglyceride levels, especially the acute elevation of FFA concentrations, might be responsible for increased cardiac fatty acid metabolism, since it has been demonstrated that fatty acids up-regulate genes 
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controlling cardiac fatty acid transport and oxidation through activation of PPAR␣ (32) . Significantly increased cardiac pyruvate dehydrogenase kinase isoenzyme 4 gene expression might be induced directly by DEX, as observed in Morris hepatoma cells (33) , leading to simultaneous suppression of cardiac glucose oxidation. Thus, increased cardiac blood glucose supply can only be metabolized by glycolysis since glucose oxidation is largely inhibited. At 7 d of age, expression most of these genes was already back to control levels. However, transient cardiac hypertrophy is prominent at this time point. Transient cardiac hypertrophy has been described in clinical trials in newborns upon GC treatment (3, 34) without delineation of a clear mechanisms. In the present study, we found that some genes involved in cardiac hypertrophy, such as ANF, desmin (35) , and TnnT2 (36), were already upregulated at 2 d of age, i.e. before the occurrence of an increased heart/body weight ratio. In addition, it has been revealed that enhanced glycolysis in cardiomyocytes may elevate endothelin-1 expression (37), which is implicated in pathologic cardiac hypertrophy (38) . Therefore, we assume that increased cardiac glycolysis and/or increased expression of cardiac cytoskeleton genes might be involved in the pathogenesis of transient cardiac hypertrophy caused by DEX administration. Only reduced gene expression of desmin persisted at 14 d of age, which may predispose to impaired cardiac function in later life, such as cardiac dilatation and heart failure (39).
In conclusion, neonatal DEX treatment has transient effects on hepatic and cardiac energy metabolism and sustained effects on plasma triglyceride and lipoprotein profiles in suckling rats. Whether these alterations predispose to hepatic abnormalities of lipid metabolism and cardiovascular disease in later life needs to be further evaluated. Although it is obviously not correct to extrapolate data from this animal experiment to human situations, data support the notion that the continued prescription of postnatal steroids should be carefully considered.
